Lilly's retatrutide beats Novo's Ozempic on blood sugar and weight in head-to-head diabetes trial
The highest retatrutide dose outperformed Ozempic but carried higher side-effect rates and discontinuations, adding to expectations the drug will be a major Lil
Biopharmadive · +13 outlets
FDA unveils draft guidance to speed approval of individualized gene editing therapies
The framework creates a pathway for patient-specific therapies and builds on recent moves aimed at faster access for rare disease treatments.
Biopharmadive · +14 outlets
Personalized mRNA melanoma vaccine cuts recurrence risk by 42% in Phase 3 trial
The positive results mark the first late-stage success for a personalized mRNA cancer vaccine and fuel hopes for wider use.
Oncology News Central · +14 outlets
FDA and CMS announce joint steps to advance gene therapies and expand rare disease access
The agencies outlined relaxed rules and access measures, with HHS Secretary Oz releasing details during a Cleveland visit.
HHS.gov · +7 outlets
Astellas to pay up to $1.34B for Melbourne startup's cancer candidate
The Japan-based pharma is betting on a Melbourne biotech's cancer therapy in one of the largest recent Australian life sciences deals.
BiotechDispatch · +3 outlets
Artiva shuts down after two patient deaths in autoimmune cell therapy trial
The closure marks the third recent fatal event in autoimmune cell therapy trials, following disclosures from Novartis and Bristol Myers Squibb.
STAT · +9 outlets
HHS moves to allow compounding of some unapproved peptides
The enforcement discretion policy follows an FDA advisory panel vote to add six peptides to a compounding list, despite limited evidence for many wellness compo
STAT · +13 outlets
FDA approves Rasonque for previously treated advanced pancreatic cancer
The clearance adds a new option for patients with advanced pancreatic cancer whose prior treatment failed.
Denkstrom · +13 outlets
Genmab soars as key cancer drug succeeds in late-stage trial
The late-stage win lifted Genmab shares and validates a key asset in its oncology pipeline.
MedWatch · +2 outlets
Ferring to acquire next-gen IVF startup Gameto for up to $1.4B
The buyout gives Ferring rights to technology aimed at simplifying the in vitro fertilization process.
Biopharmadive · +2 outlets
Court rejects Novo bid to block Lilly obesity drug ads
A federal judge ruled Novo failed to prove Lilly's superiority claims meaningfully harmed Wegovy sales.
Biopharmadive · +7 outlets
Missouri AG warns Lilly to stop requiring claims data from hospitals seeking 340B discounts
The warning signals growing state pushback against drugmaker conditions on 340B discounted medicines.
STAT · +1 outlets
California biotech Artiva folds after trial failure and two patient deaths
The biotech laid off nearly all staff in a wave of cell therapy retreats.
East Bay Times · +2 outlets
China NMPA reviews Kelun-Biotech sac-TMT and pembrolizumab combo in first-line lung cancer
The filing advances a China-developed ADC combination toward a major lung cancer indication.
BioPharma APAC · +7 outlets
GSK's B7-H3 ADC drives 67% cancer risk reduction in Hansoh Phase 3 China trial
The result bolsters GSK's ADC pipeline via its partnership with Hansoh.
Fierce Biotech · +1 outlets
Chinese drugmakers raise profile at major cancer conference
Chinese oncology companies presented record numbers of studies at ESMO 2026, with cancer vaccines and ADCs heading toward Phase 3.
South China Morning Post · +7 outlets
Merck drug extends survival in endometrial cancer trial, wins US priority review
The priority review supports Merck's oncology pipeline as it eyes 2027 catalysts.
The Hindu
Arbutus wins FDA clearance to resume hepatitis B drug trials
The clearance lets Arbutus restart clinical work on its hepatitis B candidate.
MyChesCo · +1 outlets